14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 61 days ( 0 % )
Last Price $0.470 0 %
High/ Low $0.470 - $0.470 0%
Chg 7 Days N/A $0.470 $0.470
Chg 30 Days N/A $0.470 $0.470
Chg 12 mos -77.40 % $2.08 $0.470
Trend - 3 mos N/A Width: 0.00000000 %
Trend - 12 mos -43.79 % Width: 397.63 %
Pred. range - 3 mos $0.470 - $0.470 0 % - 0 %
Pred. range - 12 mos N/A - $0.92 -100.00 % - 94.83 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Sell Apr 12, 2023 - 89 days
Long MA avg 12 mos Sell Mar 01, 2023 - 118 days
Short/Long MA avg 12 mos Sell Mar 14, 2023 - 109 days
Pivot Short Buy Aug 16, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Celyad SA

Celyad SA Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical... CYAD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT